Study: Fewer recalls mean higher interval cancer rates
New research finds that lower screening mammography recall rates – the rates at which women are called back for additional testing based on suspicious findings – correlate with higher rates of breast cancers detected between screenings (or interval cancers). Analysis of some 5 million screening episodes from 84 screening facilities in the UK showed average recall rate of 4.56 percent, with an interval cancer rate of 3.1 per 1,000 women screened. Interval cancers are associated with a worse prognosis than screen-detected cancers.
The findings, published online in the journal Radiology, highlight the importance of establishing a minimum recall rate for breast cancer screening programmes.
The UK has established a maximum recall rate target of less than 7 percent for a patient’s first screening, also known as a prevalent screen, and less than 5 percent for incident screens, or those in which previous screening results exist. However, no such consensus exists as to a minimum recall rate, below which additional cancers would be missed.
The new study, led by Elizabeth S. Burnside, MD, MPH (University of Wisconsin School of Medicine and Public Health, Madison, Wis.) and Stephen W. Duffy, BSc, MSc (Queen Mary University of London), sought to learn more about the potential trade-offs between lower recall rates and interval cancers. A total of 5,126,689 screening episodes from the UK National Health Service Breast Screening Programme were analysed. Data were drawn from a 36-month period with a three-year follow-up in women ages 50 to 70 years.
Recall rate averaged 4.56 percent, with an interval cancer rate of 3.1 per 1,000 women screened. Lower recall rates were associated with higher interval cancer rates. The researchers estimated that, in aggregate, 80 to 84 additional recalls would be required to avoid one interval cancer, a ratio that varied based on age group and prevalent screens versus incident screens.
Screening mammography outcomes based on age indicated that both cancer detection rates and interval cancer rates were lower in younger age groups as expected, based on underlying breast cancer incidence according to age.
“Recall rate had more of an impact on interval cancer in patients who are older,” Dr. Burnside said. “The lower number of recalls required per interval cancer avoided in older women and incident screens as compared to younger women and prevalent screens, respectively, demonstrates a slightly different ‘value’ in terms of the trade-off between recall rate and interval cancers.”
Additional research is needed to determine a specific minimum threshold for recall rate and assess the impact of digital mammography on the relationship between recall rate and interval cancers.
Source: Radiological Society of North America
Image Credit: Pixabay
Published on : Tue, 3 Apr 2018
Introducing a new chapter in ultrasound visualization technology. X-Porte was developed from the ground up to incorporate a breakthrough, proprietary beam-forming technology: XDI (Extreme Definition Imaging). This signal analysis algorithm shapes...
BioZorb® 3D Bioabsorbable Marker The BioZorb® is a 3D implantable marker that consists of a spiral, bioabsorbable framework embedded with 6 permanent, titanium clips designed to precisely mark your surgical excision site. Designed to improve outcomes...
The Next Evolution in Ultrasound, designed for high expectations ARIETTA 850 ultrasound platform responds to high expectations to answer the ever increasing demands of medical professionals. ARIETTA 850’s fundamental performance has been refined...
A breakthrough in biopsy efficiency The Brevera system streamlines the entire breast biopsy process from start to finish – with real-time imaging for instant verification and automated post-biopsy specimen handling. This has the potential to...
The SonoSite EDGE II is a high-resolution, all-digital, 9.0-pound (4.1 kg) ultrasound system with a 12.1in. LED full-bleed glass display. The Edge II boosts improvements in cardiac and abdominal image quality through DirectClear Technology and a new...